Basal cell carcinoma
Item
Does the participant have at least one BCC, > 5 mm, eligible for Mohs surgical removal? (participants with BCCs that have been treated before (recurrent bccs, bccs that failed other chemotherapy) are eligible for this trial, if they meet size criteria)
boolean
C0007117 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
C0079850 (UMLS CUI [1,3])
C0007117 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C2945760 (UMLS CUI [2,3])
C1548635 (UMLS CUI [2,4])
C0243161 (UMLS CUI [2,5])
C0456389 (UMLS CUI [2,6])
C0007117 (UMLS CUI [3,1])
C1514463 (UMLS CUI [3,2])
C3665472 (UMLS CUI [3,3])
C0231175 (UMLS CUI [3,4])
C1548635 (UMLS CUI [3,5])
C0243161 (UMLS CUI [3,6])
C0456389 (UMLS CUI [3,7])
Performance Status
Item
Will no eastern cooperative oncology group (ecog) or karnofsky performance status be employed?
boolean
C0445107 (UMLS CUI [1,1])
C3541269 (UMLS CUI [1,2])
C0445107 (UMLS CUI [2,1])
C0206065 (UMLS CUI [2,2])
Hepatic function
Item
Does the participant have normal hepatic function: aspartate aminotransferase (ast) and alanine aminotransferase (alt) =< 2 x the upper limit of normal (uln)?
boolean
C0232741 (UMLS CUI [1,1])
C0201899 (UMLS CUI [1,2])
C0201836 (UMLS CUI [2,1])
C1519815 (UMLS CUI [2,2])
Renal function
Item
Does the participant have normal renal function : normal serum creatinine defined as <= 2.5 mg/dl?
boolean
C0232804 (UMLS CUI [1,1])
C0600061 (UMLS CUI [1,2])
C0205307 (UMLS CUI [1,3])
Complete Blood Count
Item
Does the participant have a clinically acceptable complete blood count (cbc)?
boolean
C0009555 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
Informed consent
Item
ability to understand and the willingness to sign a written informed consent document
boolean
C1273101 (UMLS CUI [1,1])
C0009797 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C0600109 (UMLS CUI [2,1])
C0742766 (UMLS CUI [2,2])
C0021430 (UMLS CUI [2,3])
Willingness for Surgical Treatment
Item
Is the participant willing to forego surgical treatment of bccs by up to 6 months, except when the principal investigator (pi) believes that delay in treatment potentially might compromise the health of the subject?
boolean
C0600109 (UMLS CUI [1,1])
C0543467 (UMLS CUI [1,2])
C0007117 (UMLS CUI [1,3])
C0332300 (UMLS CUI [1,4])
C1521895 (UMLS CUI [1,5])
C0004951 (UMLS CUI [1,6])
C0522486 (UMLS CUI [1,7])
C2945640 (UMLS CUI [1,8])
C0018684 (UMLS CUI [1,9])
Negative pregancy test and contraception
Item
Does the participant have documented negative serum pregnancy test for women of childbearing potential, with agreement to the use of two acceptable methods of contraception during the study and for 7 months after discontinuation of vismodegib?
boolean
C1301725 (UMLS CUI [1,1])
C0427780 (UMLS CUI [1,2])
C4324275 (UMLS CUI [1,3])
C0004764 (UMLS CUI [1,4])
C0439064 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C0008976 (UMLS CUI [1,7])
C1948053 (UMLS CUI [1,8])
C0687676 (UMLS CUI [1,9])
C4288399 (UMLS CUI [1,10])
Male contraception
Item
for men with female partners of childbearing potential, agreement to use a latex, non-latex, or any other male condom and to advise their female partners to use an additional acceptable method of birth control during the study and for 2 months after discontinuation of study drug
boolean
C0009653 (UMLS CUI [1,1])
C0682323 (UMLS CUI [1,2])
C0043210 (UMLS CUI [1,3])
C1524062 (UMLS CUI [1,4])
C0700589 (UMLS CUI [1,5])
C0347984 (UMLS CUI [1,6])
C0008976 (UMLS CUI [1,7])
C1948053 (UMLS CUI [1,8])
C0687676 (UMLS CUI [1,9])
C4288399 (UMLS CUI [1,10])
No Blood or Semen donations
Item
Is the participant willing to not donate blood or semen for three months following discontinuation of study medications?
boolean
C0600109 (UMLS CUI [1,1])
C3840725 (UMLS CUI [1,2])
C0871414 (UMLS CUI [1,3])
C1948053 (UMLS CUI [1,4])
C0687676 (UMLS CUI [1,5])
C4288399 (UMLS CUI [1,6])
C0600109 (UMLS CUI [2,1])
C3840725 (UMLS CUI [2,2])
C0005794 (UMLS CUI [2,3])
C1948053 (UMLS CUI [2,4])
C0687676 (UMLS CUI [2,5])
C4288399 (UMLS CUI [2,6])
History of invasive cancer
Item
Does the participant have a history of invasive cancer within the past five years excluding non-melanoma skin cancer, stage i cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (cll) stage 0?
boolean
C0262926 (UMLS CUI [1,1])
C0677898 (UMLS CUI [1,2])
C2828389 (UMLS CUI [1,3])
C0007114 (UMLS CUI [1,4])
C0332288 (UMLS CUI [1,5])
C0025202 (UMLS CUI [1,6])
C0262926 (UMLS CUI [2,1])
C0677898 (UMLS CUI [2,2])
C2828389 (UMLS CUI [2,3])
C0278575 (UMLS CUI [2,4])
C0262926 (UMLS CUI [3,1])
C0677898 (UMLS CUI [3,2])
C2828389 (UMLS CUI [3,3])
C1527349 (UMLS CUI [3,4])
C0262926 (UMLS CUI [4,1])
C0677898 (UMLS CUI [4,2])
C2828389 (UMLS CUI [4,3])
C0023434 (UMLS CUI [4,4])
C0441763 (UMLS CUI [4,5])
Uncontrolled systemic disease
Item
Does the participant have uncontrolled systemic disease, including known human immunodeficiency virus (hiv) positive patients?
boolean
C0442893 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
C0019699 (UMLS CUI [1,4])
Congestive Heart Failure
Item
Does the participant have a history of congestive heart failure?
boolean
C0262926 (UMLS CUI [1,1])
C0018802 (UMLS CUI [1,2])
Relevant Liver Disease
Item
Does the participant have clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis?
boolean
C0262926 (UMLS CUI [1,1])
C0023895 (UMLS CUI [1,2])
C3898777 (UMLS CUI [1,3])
C1512693 (UMLS CUI [1,4])
C0019158 (UMLS CUI [1,5])
C0262926 (UMLS CUI [2,1])
C0023895 (UMLS CUI [2,2])
C3898777 (UMLS CUI [2,3])
C1512693 (UMLS CUI [2,4])
C0042721 (UMLS CUI [2,5])
C0262926 (UMLS CUI [3,1])
C0023895 (UMLS CUI [3,2])
C3898777 (UMLS CUI [3,3])
C1512693 (UMLS CUI [3,4])
C0521116 (UMLS CUI [3,5])
C0085762 (UMLS CUI [3,6])
C0262926 (UMLS CUI [4,1])
C0023895 (UMLS CUI [4,2])
C3898777 (UMLS CUI [4,3])
C1512693 (UMLS CUI [4,4])
C1623038 (UMLS CUI [4,5])
Patient unfit for study
Item
Does the participant have any condition or situation which in the investigator's opinion may put the patient at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study; this includes history of other skin conditions or disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications?
boolean
C0348080 (UMLS CUI [1,1])
C0008961 (UMLS CUI [1,2])
C0871010 (UMLS CUI [1,3])
C0035647 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C0008961 (UMLS CUI [2,2])
C0871010 (UMLS CUI [2,3])
C0009673 (UMLS CUI [2,4])
C0348080 (UMLS CUI [3,1])
C0008961 (UMLS CUI [3,2])
C0871010 (UMLS CUI [3,3])
C0521102 (UMLS CUI [3,4])
C2348568 (UMLS CUI [3,5])
C1512693 (UMLS CUI [4,1])
C1719933 (UMLS CUI [4,2])
C2362507 (UMLS CUI [5])
C0031809 (UMLS CUI [6])
C4505474 (UMLS CUI [7])
C0522473 (UMLS CUI [8,1])
C0013230 (UMLS CUI [8,2])
C0392760 (UMLS CUI [9,1])
C0459471 (UMLS CUI [9,2])
C0683954 (UMLS CUI [9,3])
C0332167 (UMLS CUI [10,1])
C0679861 (UMLS CUI [10,2])
Hypersensitivity to study medication
Item
Does the participant have a history of hypersensitivity to any of the ingredients in the study medication formulations?
boolean
C0020517 (UMLS CUI [1,1])
C0085993 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,3])
Abstaining from topical drugs
Item
Is the participant willing to abstain from application of non-study topical medications to the skin for the duration of the study, including prescription and over the counter preparations; for example, topical preparations containing corticosteroids or vitamin a derivatives are not allowed?
boolean
C0600109 (UMLS CUI [1,1])
C1705537 (UMLS CUI [1,2])
C1524063 (UMLS CUI [1,3])
C1522168 (UMLS CUI [1,4])
C0347984 (UMLS CUI [1,5])
C0008976 (UMLS CUI [1,6])
C0304604 (UMLS CUI [2])
C3892279 (UMLS CUI [3])
Pregnant or Nursing
Item
Is the patient pregnant or nursing?
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])